Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Journey Medical (NASDAQ:DERM) released its quarterly earnings results on Wednesday. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30, Zacks reports. The firm had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Journey Medical Price Performance

Shares of DERM traded up $0.07 during mid-day trading on Friday, hitting $5.99. 21,587 shares of the company traded hands, compared to its average volume of 86,303. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $125.13 million, a price-to-earnings ratio of -6.37 and a beta of 0.97. The business has a 50-day moving average of $5.05 and a 200 day moving average of $5.16. Journey Medical has a one year low of $3.20 and a one year high of $6.89.

Analysts Set New Price Targets

Separately, Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a report on Thursday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $9.67.

Insider Buying and Selling

In other news, CEO Claude Maraoui sold 18,147 shares of Journey Medical stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total value of $93,094.11. Following the completion of the sale, the chief executive officer now directly owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. This trade represents a 0.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 105,831 shares of company stock worth $536,622 in the last quarter. Insiders own 13.16% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.